CD274 and cancer: The spectacular success of PD-L1 targeting monoclonal antibodies in cancer therapy has kindled significant interest in investigating the possible utility of PD-L1 as a diagnostic marker for imaging, a selection marker for antibody therapy [15] and for monitoring of treatment.